Newsfiscal.ai
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
· Published
Article summary
Allogene Therapeutics has scheduled its third quarter 2026 financial results call for November 5 and a webinar to present preliminary data from its ALLO-329 autoimmune program on November 9.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…